Anticancer Drug-Induced Paronychia (Grade 1 or 2) Paronychia (D010270) Antineoplastic Agents/adverse effects (D000970) Laser Therapy (D008012) Dermatologic Agents/therapeutic use (D003882) Nail Diseases/therapy (D009259) Epidermal Growth Factor Receptor Antagonists/adverse effects (D053685) Drug-Related Side Effects and Adverse Reactions (D064806) Oncology (D009369)
Conditions
Interventions
pulse-dyed laser (595 nanometer wavelength) (Vbeam Perfecta, Candela Corporation, Marlborough, MA, USA) parameter: spot size of 7 mm, pulse width of 1.5 ms, fluence of 6.0 to 6.5 Jpercm2 non overlappi
Experimental Procedure/Surgery
adjunctive pulse dyded laser
Sponsors
Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion Criteria for Research Participation 1. Male or female volunteers aged 18 years or older. 2. Volunteers diagnosed with paronychia induced by taxanes, epidermal growth factor receptor (EGFR) inhibitors, EGFR tyrosine kinase inhibitors, tyrosine kinase inhibitors, MEK/ERK inhibitors, BRAF inhibitors, CD20 antagonists, or vascular endothelial growth factor (VEGF) inhibitors, with a severity grade of 1 or 2, who have received at least 2 weeks of standard treatment with stable symptoms. 3. Volunteers must continue receiving taxanes, EGFR inhibitors, EGFR tyrosine kinase inhibitors, tyrosine kinase inhibitors, MEK/ERK inhibitors, BRAF inhibitors, CD20 antagonists, or VEGF inhibitors, which contribute to paronychia, throughout the study period. 4. Volunteers must be willing to comply with medical recommendations following treatment. 5. Volunteers must provide written informed consent to participate in the research.
Exclusion criteria
Exclusion criteria: Exclusion criteria were active nail infections, unrelated nail disorders, contraindications to laser therapy, or severe comorbid conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in erythema index (EI) at baseline, weekly during the treatment, and two weeks post-treatment. hemoglobin level by Antera 3D imaging | — |
Secondary
| Measure | Time frame |
|---|---|
| Physician Global Assessment (PGA) at baseline, weekly during the treatment, and two weeks post-treatment. Physician Global Asseevaluated through blinded photographic analysis by three dermatologists using a quartile grading scale ,SPOT severity score at baseline, weekly during the treatment, and two weeks post-treatment. clinically assessed by the primary investigator based on erythema, edema, discharge, and granulation tissue ,pain score at baseline, weekly during the treatment, and two weeks post-treatment. Visual Analogue Scale ,patient satisfaction at baseline, weekly during the treatment, and two weeks post-treatment. quartile scale,periungual swelling volume at baseline, weekly during the treatment, and two weeks post-treatment. Antera 3D as elevation volume | — |
Countries
Thailand
Contacts
Public ContactPawinee Rerknimitr
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed